Move to Nano-Arthrology: Targeted Stimuli-Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis

Biotechnology Journal
Lu LiuXing-Jie Liang

Abstract

Rheumatoid arthritis (RA) is one of the most popular chronic autoimmune diseases characterized with persistent synovial inflammation and bone destruction. Although considerable developments have been gained in clinical treatment of RA, the major drawback to RA therapy stems from the adaptive treatment tolerance (ATT) following the long-term drug use, which causes compromised efficacy, sustained drug dose increase, and severe adverse events. To address these challenges, it is of great significance to put forward innovative therapeutic approaches for RA treatment. Nowadays, developments of nanotechnology-based nanomedicines (NMs) for RA are in progress. Multifunctional NMs with targeted stimuli-responsive features have been one of the central concepts in designing more accessible formulations for efficient RA treatment. These NMs are able to postpone RA progression effectively, because of their delivery and on-demand release of medicaments at targeted sites in response to external or internal stimuli related to the RA pathophysiology without obvious adverse side-effects on the normal tissues. Therefore, NMs have gained interest from pre-clinical research scientists as well as clinical doctors worldwide. Herein, the authors highli...Continue Reading

References

Apr 1, 1990·American Journal of Respiratory Cell and Molecular Biology·P D Stahl
May 1, 1971·Annals of the Rheumatic Diseases·F C BallantyneW C Dick
Jan 1, 1969·Acta Orthopaedica Scandinavica·I Goldie, A Nachemson
Jul 1, 1971·Arthritis and Rheumatism·P S Treuhaft, D J MCCarty
Jun 1, 1994·British Journal of Rheumatology·A S WilliamsB D Williams
Nov 1, 1996·Chemistry & Biology·S Strömblad, D A Cheresh
Feb 24, 1999·Nature·C D BuckleyM Salmon
May 16, 2003·Nature·Gary S Firestein
May 31, 2003·Nature Reviews. Drug Discovery·Josef S Smolen, Günter Steiner
Dec 5, 2003·Trends in Pharmacological Sciences·Holger UlbrichLennart Lindbom
Feb 5, 2005·Nature Reviews. Drug Discovery·Claire Mount, James Featherstone
Sep 9, 2005·Frontiers in Bioscience : a Journal and Virtual Library·Peter S BurrageConstance E Brinckerhoff
May 26, 2007·Nature Reviews. Immunology·Iain B McInnes, Georg Schett
Jun 21, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·John J RyanChristopher L Kepley
Oct 25, 2007·Clinical Pharmacology and Therapeutics·L ZhangO C Farokhzad
Jun 24, 2008·Purinergic Signalling·William A CarrollMichael F Jarvis
Jun 28, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Felix Kratz
Aug 2, 2008·Nature Reviews. Drug Discovery·Gil Y MelmedPeter Kirkpatrick
Dec 11, 2008·Annals of the Rheumatic Diseases·J N HoesG J M G Van der Heijden
Feb 27, 2009·The Journal of Pharmacology and Experimental Therapeutics·Tsutomu IshiharaMegumu Higaki
Sep 2, 2009·Nature Reviews. Drug Discovery·Jeffrey G Stoll, Uma Yasothan
Nov 27, 2009·Journal of the Royal Society, Interface·Wiebke Ulbrich, Alf Lamprecht
Feb 6, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Cheryl A Thompson
Mar 3, 2010·Immunological Reviews·Sook Kyung ChangMichael B Brenner
Jul 24, 2010·Nature Reviews. Immunology·John D Isaacs
Sep 28, 2010·Lancet·David L ScottTom W J Huizinga
Oct 21, 2010·Annals of the Rheumatic Diseases·Iain B McInnes, James R O'Dell
Jan 5, 2011·Nature Reviews. Drug Discovery·Naomi SchlesingerPeter Kirkpatrick
Jul 2, 2011·Nanomedicine·Jesse V JokerstSanjiv S Gambhir
Dec 6, 2012·Molecular Pharmaceutics·Varun SethiHayat Onyuksel
Mar 16, 2013·Current Opinion in Rheumatology·Costantino PitzalisFrances Humby
Jul 25, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Young-Seok JungKun Na
Oct 26, 2013·International Journal of Pharmaceutics·Alexandra RollettGeorg M Guebitz
Oct 26, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Min Ley PuaYukio Nagasaki
Oct 30, 2013·Drug Development and Industrial Pharmacy·Upasana BilthariyaAshish Kumar Jain
Mar 19, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Felix Kratz
Mar 25, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jin Hee KangYoung Mo Kang
Jun 5, 2014·Chemical Communications : Chem Comm·Jung Min ShinJae Hyung Park
Aug 12, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Roun HeoJae Hyung Park
Aug 28, 2014·Frontiers in Physiology·Angelica M MerlotDes R Richardson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

© 2022 Meta ULC. All rights reserved